Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis. Sorafenib is the only approved systemic chemotherapeutic drug for patients with advanced HCC. Previous studies have shown that androgen and androgen receptor (AR) are involved in human hepatocarcinogenesis and the develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Tatsuo, Takahashi, Koji, Nakamura, Masato, Nakamoto, Shingo, Wu, Shuang, Haga, Yuki, Sasaki, Reina, Jiang, Xia, Yokosuka, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447953/
https://www.ncbi.nlm.nih.gov/pubmed/28475115
http://dx.doi.org/10.3390/cancers9050043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447953/
https://www.ncbi.nlm.nih.gov/pubmed/28475115
http://dx.doi.org/10.3390/cancers9050043

Ejemplares similares